DOI QR코드

DOI QR Code

Predictive Factors Determining Neoadjuvant Chemotherapy Outcomes in Breast Cancer - a Single Center Experience

  • Yu, Yang (Department of Breast Surgery, Zhejiang Cancer Hospital) ;
  • Xiang, Hua (Department of Pathology, First Affiliated Hospital of College of Medicine, Zhejiang University) ;
  • He, Xiang-Ming (Department of Breast Surgery, Zhejiang Cancer Hospital) ;
  • Yang, Hong-Jian (Department of Breast Surgery, Zhejiang Cancer Hospital) ;
  • Zong, Xiang-Yun (Department of Breast Surgery, Shanghai 6th Hospital, Shanghai Jiaotong University School of Medicine)
  • 발행 : 2013.04.30

초록

From January 1, 2008 to March 31, 2010, 101 patients with stage II-III breast cancer were enrolled in this study and subjected to an anthracycline-based neoadjuvant chemotherapy regimen with or without docetaxel. Surgery was performed after 2-6 cycles of chemotherapy, and the clinical response was determined by pathological and histochemical assessments. The clinical response rate, as indicated by complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), were 6.9, 52.5, 36.6, and 4.0%, respectively. A multivariable correlation analysis indicated that the overall clinical response rate correlated with the number of metastatic lymph nodes, number of chemotherapy cycles, and vessel invasion status. Importantly, the CR rate was only associated with the number of chemotherapy cycles. Nonparametric tests failed to detect a correlation between HER2 or Topo $II{\alpha}$ status and clinical response to neoadjuvant chemotherapy in these patients. When they were stratified by HER2 or HR status, for HER2-positive patients the CR rate was associated with vessel invasion and Topo $II{\alpha}$ status. Based on our findings, we propose that HR, HER-2 and Topo $II{\alpha}$ are not putative predictive biomarkers of chemotherapy outcome for breast cancer patients. Topo $II{\alpha}$ expression level was only inversely correlated with CR rate among HR-positive patients. Importantly, the achievement of CR was largely related to the number of chemotherapy cycles.

과제정보

연구 과제 주관 기관 : Zhejiang Natural Scientific Fundation

참고문헌

  1. Li XR, Liu M, Zhang YJ, Wang JD, et al (2011). ER, PgR, HER-2, Ki-67, topoisomerase II${\alpha}$, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med Oncol, 1, S48-54.
  2. Lips EH, Mulder L, de Ronde JJ, Mandjes IA, et al (2012). Neoadjuvant chemotherapy in ER+ HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat, 131, 827-36. https://doi.org/10.1007/s10549-011-1488-0
  3. Moreno-Aspitia A (2012). Neoadjuvant therapy in early-stage breast cancer. Crit Rev Oncol Hematol, 82, 187-99. https://doi.org/10.1016/j.critrevonc.2011.04.013
  4. Munro AF, Cameron DA, Bartlett JM (2010). Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene, 29, 5231-40. https://doi.org/10.1038/onc.2010.286
  5. Ng AK, Travis LB (2009). Radiation therapy and breast cancer risk. J Natl Compr Canc Netw, 7, 1121-8.
  6. Oshima K, Naoi Y, Kishi K, Nakamura Y, et al (2011). Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/ epirubicin/cyclophosphamide in human breast cancer. Cancer Lett, 307, 149-57. https://doi.org/10.1016/j.canlet.2011.03.027
  7. Petrarca CR, Brunetto AT, Duval V, Brondani A, et al (2011). Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin Breast Cancer, 11, 129-34. https://doi.org/10.1016/j.clbc.2011.03.002
  8. Rastogi P, Anderson SJ, Bear HD, Geyer CE, et al (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85. https://doi.org/10.1200/JCO.2007.15.0235
  9. Untch M, von Minckwitz G (2011). Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological. J Natl Cancer Inst Monogr, 43, 138-41.
  10. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001). Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr, 30, 96-102.
  11. Wu J, Li S, Jia W, Su F (2011). Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol, 137, 1505-10. https://doi.org/10.1007/s00432-011-1029-6
  12. Zhu L, Li YF, Chen WG, He JR, et al (2008). HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J (Engl), 121, 1965-8.
  13. Aigner J, Schneeweiss A, Sohn C, Marme F (2011). The role of neoadjuvant chemotherapy in the management of primary breast cancer. Minerva Ginecol, 63, 261-74.
  14. Arpino G, Ciocca DR, Weiss H, Allred DC, et al (2005). Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat, 92, 69-75. https://doi.org/10.1007/s10549-005-1721-9
  15. Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, et al (2011). TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol, 12, 527-39. https://doi.org/10.1016/S1470-2045(11)70094-8
  16. Coon JS, Marcus E, Gupta-Burt S, Seelig S, et al (2002). Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res, 8, 1061-7.
  17. Di Leo A, Gancberg D, Larsimont D, Tanner M, et al (2002). HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracyclinebased therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res, 8, 1107-16.
  18. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, et al (2001). HER-2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol, 12, 1081-9. https://doi.org/10.1023/A:1011669223035
  19. Dowsett M, Nielsen TO, A'hern R, Bartlett J, et al (2011). Assessment of ki67 in breast cancer: recommendations from the international ki67 in breast cancer working group. J Natl Cancer Inst, 103, 1656-64. https://doi.org/10.1093/jnci/djr393
  20. Du Y, Zhou Q, Yin W, Zhou L, et al (2011). The role of topoisomerase II${\alpha}$ in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Breast Cancer Res Treat, 129, 839-48. https://doi.org/10.1007/s10549-011-1694-9
  21. Duffaud F, Therasse P (2000). New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer, 87, 881-6.
  22. Fritz P, Cabrera CM, Dippon J, Gerteis A, et al (2005). c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res, 7, R374-84. https://doi.org/10.1186/bcr1012
  23. Generali D, Symmans WF, Berruti A, Fox SB (2011). Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. J Natl Cancer Inst Monogr, 43, 99-102.
  24. Glynn RW, Mahon S, Curran C, Callagy G, et al (2011). TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer. Oncologist, 16, 949-55. https://doi.org/10.1634/theoncologist.2011-0071
  25. Gnant M, Harbeck N, Thomssen C (2011). St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel), 6, 136-41. https://doi.org/10.1159/000328054
  26. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, et al (2009). Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol, 27, 3430-6. https://doi.org/10.1200/JCO.2008.18.4085
  27. Harris LN, Yang L, Liotcheva V, Pauli S, et al (2001). Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res, 7, 1497-504.
  28. Jarvinen TA, Holli K, Kuukasjarvi T, Isola JJ (1998). Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer, 77, 2267-73. https://doi.org/10.1038/bjc.1998.377
  29. Jarvinen TA, Liu ET (2003). HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat, 78, 299-311. https://doi.org/10.1023/A:1023077507295
  30. Jarvinen TA, Tanner M, Rantanen V, Barlund M, et al (2000). Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol, 156, 839-47. https://doi.org/10.1016/S0002-9440(10)64952-8
  31. Jiang ZF, Wang T (2009). An interpretation of the China edition of National Comprehensive Cancer Network(NCCN) clinical practice guideline for breast cancer. [Article in Chinese] Zhonghua Wai Ke Za Zhi, 47, 485-7.
  32. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, et al (2005). retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol, 23, 7483-90. https://doi.org/10.1200/JCO.2005.11.007
  33. Kong X, Moran MS, Zhang N, Haffty B, Yang Q (2011). Metaanalysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer, 47, 2084-90. https://doi.org/10.1016/j.ejca.2011.06.014
  34. Kurosumi M (2004). Significance of histopathological evaluation in primary therapy for breast cancer--recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer, 11, 139-47. https://doi.org/10.1007/BF02968293
  35. Kurosumi M (2006). Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer, 13, 254-9. https://doi.org/10.2325/jbcs.13.254
  36. Leong SP, Shen ZZ, Liu TJ, Agarwal G, et al (2010). Is breast cancer the same disease in Asian and Western countries? World J Surg, 34, 2308-24. https://doi.org/10.1007/s00268-010-0683-1

피인용 문헌

  1. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population vol.31, pp.9, 2014, https://doi.org/10.1007/s12032-014-0165-7
  2. Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Positivity and Numbers in Breast Cancer Cases vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1181